# **CME INFORMATION**

Physicians' Research Network Meeting: September 23, 2020, jointly provided by the Medical Society of the State of New York 7:00 PM -- 9:00 PM (*EST*), Webinar via Zoom video conferencing platform

Target Audience: Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.

Course Director: James F. Braun, DO, President, Physicians' Research Network, 39 West 19th St., Suite 605, NY, NY 10011

Moderator: William M. Valenti, MD, Physicians' Research Network, 39 West 19th St., Suite 605, NY, NY 10011

### Faculty Introductions and Disclosures: Dr. Valenti

Guest Speakers and Presentations: Dr. Toribio at 7:00 PM (EST) - Dr. Branson at 8:00 PM (EST)

## Atherosclerotic Cardiovascular Disease in HIV: Special Focus on Transgender and Cisgender Women

Mabel Toribio, MD, PhD Instructor in Medicine Massachusetts General Hospital Boston MA

#### Learning Objectives:

#### At the completion of this program, participants will:

- 1. To describe mechanisms of heightened atherosclerotic cardiovascular disease among people living with HIV.
- 2. To discuss prevention and treatment strategies under investigation to mitigate atherosclerotic cardiovascular disease.
- 3. To describe specific populations, i.e. transgender and cisgender women living with HIV, that may be at high risk for cardiovascular disease.

- and -

## Testing for HIV and COVID-19: It Is What It Is

Bernard M Branson MD Principal Consultant Scientific Affairs LLC Atlanta, GA

## Learning Objectives:

#### At the completion of this program, participants will be able to:

- 1. Understand the fundamentals of laboratory tests for COVID-19.
- 2. Appreciate the role for serology tests in identifying exposure to COVID-19.
- 3. Review new developments in HIV tests and their utility for a new diagnostic algorithm.
- 4. Describe how similar parameters affect the accuracy of tests for COVID-19 and HIV.

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians' Research Network (PRN). The Medical Society of the State of New York (MSSNY) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing Medical Education for physicians.

The Medical Society of the State of New York (MSSNY) designates this live activity for a maximum of *2.0 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement**: Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity. Dr. Braun (Planner/Course Director) has no relevant financial relationships to disclose. Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. Dr. Mabel Toribio (Presenter) has no relevant financial relationships to disclose. Dr. Toribio will support her presentation and clinical recommendations with the best available evidence from the medical literature, and will submit her slides in advance for adequate peer review. Dr.Bernard M. Branson (Presenter) has no relevant financial relationships to disclose. Dr. Branson will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will support his presentation and clinical recommendations with the best available evidence from the medical is in advance for adequate peer review.

Financial Support: This PRN CME activity is funded in part by unrestricted educational grants from: Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare